STRC Research

Tafamidis Kinetic-Stabilization Paradigm

3 min read

Tafamidis Kinetic-Stabilization Paradigm

Distilled from DR1 — Pharmacochaperone Clinical Precedents §1. The foundational FDA proof-of-concept (EMA 2011, FDA 2019) for kinetic stabilization of a misfolding protein, and the regulatory benchmark for “stabilization is the mechanism” claims.

The principle

Tafamidis (benzoxazole, MW 308.2, logP 3.91) does not lower equilibrium ΔG of the folded TTR tetramer in any meaningful drug-action sense — it raises the kinetic barrier to the rate-limiting unfolding step. TTR amyloidogenesis is rate-limited by tetramer → monomer dissociation; once monomers form, downstream aggregation is fast. Tafamidis binds at the dimer-dimer interface (the two thyroxine sites), forming an H-bond to Ser52 in the CD loop, and freezes the tetramer kinetically. Phase 3 ATTR-ACT (n=441): 30% all-cause-mortality reduction, 32% cardiovascular hospitalization reduction over 30 months.

Generalizable form: identify the rate-limiting step on the misfolding/QC reaction coordinate, design the drug to bind a state on that step’s reaction-coordinate maximum, and measure the barrier shift — not the equilibrium ΔΔG.

Why H01 has not yet framed this

H01’s mechanistic argument is a thermodynamic claim: K1141 pocket APBS preference for formal-anion ligands, −2.79 kcal/mol matched-ensemble (Phase 5k, p=6.9e-12). This says “the bound state is favored”. It does not say which step on the E1659A QC reaction coordinate the binding intercepts:

  • Co-translational ER folding (calnexin cycle entry)?
  • Post-folding QC inspection (calreticulin glucose trimming)?
  • ERAD substrate selection (BiP/Hsp70 client transfer)?
  • Membrane-anchored release into the cochlear extracellular space (post-trafficking conformational maturation)?

Each step has its own rate-limit. Tafamidis works because the TTR rate-limit is tetramer dissociation, and the drug binds the pre-dissociation state. For E1659A, the rate-limiting step on the QC pathway is not yet identified in any H01 phase. The K1141 pocket may sit on or off the relevant reaction coordinate.

Operational implication

A paper-§3 claim that “Coulomb-aware K1141 binding rescues E1659A folding” requires either:

  1. Identifying the rate-limiting QC step (e.g., via pulse-chase with calnexin/calreticulin/EDEM co-IP), or
  2. A purely empirical Δ-trafficking readout (the Migalastat / Vertex playbook — see Migalastat Dosing-Cycle Principle and STRC h01 Phase 8 Wet-Lab Triage SOP) that side-steps mechanism-step assignment.

Path (1) is the rigorous Tafamidis-style argument; path (2) is the regulatory minimum. The paper as currently drafted (STRC Paper Draft Outline 2026-04-25) is closer to (2) and should not over-claim Tafamidis-level mechanistic specificity until the rate-limiting step is named.

Regulatory precedent value

Tafamidis established that ex vivo biophysical stabilization assays (fluorescent probe exclusion + mass spec to quantify tetramer fraction at peak/trough plasma concentrations) are accepted by FDA and EMA as a valid PD surrogate. For H01, the analogous package would be:

  • DSF / nano-DSF on purified E1659A vs. WT ± lead compound → ΔTm
  • Native-MS or SEC-MALS fold-state distribution shift
  • Pulse-chase glycoform maturation Western (the Migalastat 2018 FDA template)

These are wet-lab, not compute, but the regulatory framework already exists.

Connections

Graph View

Backlinks